Drug
Zeprumetostat clinical trials
Also written SHR2554.
- studies test it
- 34
- open now
- 24
- in phase 3
- 1
- first study started
- 2018
Keep track of what changes. Save the zeprumetostat studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
34 studies that test it; most in 2026 (11)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2022 | 2 |
| 2023 | 5 |
| 2024 | 6 |
| 2025 | 4 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 19
- Phase 2
- 22
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 20
Jiangsu HengRui Medicine Co., Ltd. (13) · Fudan University (4) · Institute of Hematology & Blood Diseases Hospital, China (3) · Sun Yat-sen University (2) · Ruijin Hospital (2) · Chinese PLA General Hospital (2) · Treeline Biosciences, Inc. (1) · Peking University First Hospital (1)
Often tested with
Tested in the same studies.
SHR-1701 (6) · Apatinib (3) · Tucidinostat (2) · Linperlisib (2) · Azacitidine (2) · Camrelizumab (2) · Fluconazole (1) · Itraconazole (1)
Studies
Open first, then newest update. How each study uses zeprumetostat is read from its arms, and is right about nine times in ten.
Testing it · 34
- SHR2554 Combined With Endocrine Therapy in Advanced Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT07125950Written as SHR2554
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingPhase 2Fudan UniversityNCT07874425Written as zeprumetostat
- A Prospective Clinical Study of Zeprumetosta in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaNot yet recruitingPhase 2Peking University First HospitalNCT07854639Written as Zeprumetostat Tablets
- A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte LeukemiaNot yet recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT07692529Written as zeprumetostat
- PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingPhase 2The First Affiliated Hospital of Zhengzhou UniversityNCT07294664Written as SHR2554
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07717242Written as Zeprumetostat
- Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell LymphomaRecruitingPhase 1/2Rong TaoNCT07502768Written as Zeprumetostat
- Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular LymphomaRecruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07555470Written as Zeprumetostat
- Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell LymphomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07615283Written as Adebrelimab & SHR2554
- Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07493330Written as Zeprumetostat+Decitabine
- Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell LymphomaRecruitingPhase 2Fudan UniversityNCT06519526Written as SHR-2554
- A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate CancerRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07230106Written as SHR2554 Tablet
- Zeprumetostat, Azacitidine Combined With Lipo-MIT in R/R PTCLRecruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07372352Written as Zeprumetostat
- SHR2554 as Maintenance Therapy in Patients With Peripheral T-cell LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07347288Written as SHR2554 Tablets
- EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07339527Written as Zeprumetostat
- SHR2554 Clinical Study of Chidamide in the Treatment of T-cell LymphomaRecruitingPhase 3Jiangsu HengRui Medicine Co., Ltd.NCT06122389Written as SHR2554; Chidamide analog tablets
- Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer SubjectsRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07175220Written as SHR2554; SHR-A2102
- Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL)Not yet recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT06712173Written as linperlisib and SHR2554
- SHR-1701 Combined with SHR2554 and BP102 for MCRCNot yet recruitingPhase 2Fudan UniversityNCT06679673Written as SHR2554
- A Study of SHR2554 With Chemotherapy in Treatment-naïve Patients With Peripheral T-cell LymphomaRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06173999Written as SHR2554/CHOEP
See all 34 studies that test zeprumetostat →
Given in every arm · 4 — zeprumetostat is usual care beside what is tested
- A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate CancerRecruitingPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT06568094Written as SHR2554 tablets
- TLN-121 in Relapsed or Refractory Non-Hodgkin LymphomasRecruitingPhase 1Treeline Biosciences, Inc.NCT07082803Written as zeprumetostat (TLN-254)
- Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaRecruitingPhase 2Jiangsu HengRui Medicine Co., Ltd.NCT07102901Written as SHR2554 Tablets
- A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPCTerminatedPhase 1/2Jiangsu HengRui Medicine Co., Ltd.NCT03741712Written as SHR2554
As the comparator · 1 — what is tested is compared with zeprumetostat
Codes
What other systems call zeprumetostat · ClinicalTrials.gg INT018479
- UNII (FDA) XLJ9D8HE8YZEPRUMETOSTATOne source FDA
- NCI Thesaurus C158742ZeprumetostatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | XLJ9D8HE8Y | ZEPRUMETOSTAT | One source FDA |
| NCI Thesaurus | C158742 | Zeprumetostat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.